In hospitalised COVID-19 patients, DN2 cells are associated with high neutralising antibody titres and elevated plasma concentrations of inflammatory biomarkers, such as CRP, CXCL10, and IL-6. This evidence concerns the gene CXCL10 and COVID-19.